4.4 Review

Research Progress of LncRNAs in Atrial Fibrillation

Journal

MOLECULAR BIOTECHNOLOGY
Volume 64, Issue 7, Pages 758-772

Publisher

SPRINGERNATURE
DOI: 10.1007/s12033-022-00449-5

Keywords

Atrial fibrillation; Long noncoding RNA; Differential expression; Biomarker; Therapeutic target

Funding

  1. Key Specialty of Discipline Construction Project of Shanghai Health Committee [ZK2019B25]
  2. Research Project of Science and Technology Commission of Pudong New Area [PKJ2019-Y40]

Ask authors/readers for more resources

Atrial fibrillation is a common arrhythmia with increased research in clinical diagnosis and treatment. Long noncoding RNAs have been shown to play a role in cardiovascular diseases and are gaining attention in the identification and function of atrial fibrillation.
Atrial fibrillation (AF) is one of the most common arrhythmias in adults, with high morbidity and increased mortality risk. In recent years, the clinical diagnosis, treatment, and mechanistic research of AF have increased exponentially, and regulation based on the potential molecular mechanism of AF is a research hotspot. Long noncoding RNAs (LncRNAs), usually refer to noncoding RNA transcripts greater than 200 nucleotides in length, have been shown to play a role in cardiovascular diseases such as coronary artery disease, heart failure, and myocardial fibrosis through various regulatory methods. An increasing number of researchers have begun to pay attention to the identification and function of LncRNAs in AF. This article reviews changes in the expression of related LncRNAs detected in AF and describes the LncRNAs that play a regulatory role in AF-related processes, to explore the potential of LncRNAs as new biomarkers and therapeutic targets in AF.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available